Freedom of information request on updating the Regulation 174 authorisations for the COVID-19 vaccines made by Pfizer and AstraZeneca in relation to booster doses (FOI 21/1157)
Published 26 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-1-november-2021/freedom-of-information-request-on-updating-the-regulation-174-authorisations-for-the-covid-19-vaccines-made-by-pfizer-and-astrazeneca-in-relation-to-b
FOI 21/1157
1st November 2021
Dear,
Thank you for your email.
In updating the Regulation 174 authorisations for the COVID-19 vaccines made by Pfizer and AstraZeneca in relation to booster doses, MHRA reviewed published data on immunocompromised patients, data from the manufacturers’ trials, data from the UK COV-Boost and ComFluCOV trials conducted by UK University Hospitals, and a summary of published and Public Health England (PHE) data regarding waning vaccine effectiveness. These data were reviewed by the independent Commission on Human Medicines (CHM). These data are not published yet, however, MHRA is currently updating the relevant Public Assessment Reports with these changes to the Regulation 174 authorisations. Unfortunately, due to this the information is exempt from release under section 22:
Section 22 – Information intended for future publication: the information you have requested is due to be published. Section 22 is a qualified exemption, which means that we have considered whether the public interest in releasing the information is outweighed by the public interest in not giving the information.
If you have a query about the information provided, please reply to this email
If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask for an internal review. Please reply to this email, within two months of this reply, specifying that you would like an Internal Review to be carried out.
Due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices
Please remember to quote the reference number above in any future communications.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Yours sincerely,
MHRA Customer Service Centre
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000